COVAXIN vaccine by Bharath Biotech.
The Subject Expert Committee (SEC) on COVID-19 of the CDSCO recommended the indigenously developed COVID-19 vaccine Covaxin with certain conditions, days after making similar recommendations for the Oxford vaccine manufactured in India as Covishield
COVAXIN vaccine by Bharath Biotech.
New Delhi: An expert panel of India's central drug authority on Saturday recommended granting permission for restricted emergency use of the indigenously developed vaccine Covaxin with certain conditions, a day after giving similar direction for the Oxford vaccine, sources said.
Covaxin has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
The Subject Expert Committee (SEC) on of the Central Drugs Standard Control Organisation (CDSCO) on Saturday again deliberated on the emergency use authorisation (EUA) application of the Hyderabad-based pharmaceutical firm after it submitted additional data, facts, and analysis subsequent to Friday's review meeting, a source said.
Bharat Biotech had applied to the Drugs Controller General Of India (DCGI) seeking emergency use authorisation for its Covaxin on 7 December.
On Friday, the SEC had recommended granting permission for restricted emergency use of Oxford-AstraZeneca vaccine Covishield, being manufactured by the Serum Institute of India.